Journal
JOURNAL OF NEUROIMAGING
Volume 22, Issue 4, Pages 365-374Publisher
WILEY
DOI: 10.1111/j.1552-6569.2011.00633.x
Keywords
Fornix sign; fractional anisotropy; diffusion tensor imaging; Alzheimer's disease; mild cognitive impairment
Funding
- NIH [R21AG033774, P41 RR015241, R01NS058299, R01AG20012]
- Johns Hopkins Alzheimer's Disease Research Center (NIH) [P50AG005146]
- Glaxo-Smith-Kline
- NIMH
- NIA
- Associated Jewish Federation of Baltimore
- Weinberg Foundation
- Forest
- Eisai
- Pfizer
- Astra-Zeneca
- Lilly
- Ortho-McNeil
- Bristol-Myers
- Novartis
Ask authors/readers for more resources
BACKGROUND We investigated a simple imaging sign for Alzheimer's disease (AD), using diffusion tensor imaging (DTI). We hypothesized that a reduction in fractional anisotropy (FA) in the fornix could be utilized as an imaging sign. METHODS Twenty-three patients with AD, 24 patients with amnestic mild cognitive impairment (aMCI), and 25 control participants (NC) underwent DTI at baseline and 1 year later. The diagnosis was reevaluated 1 year and 3 years after the initial scan. A color-scaled FA map was used to visually identify the FA reduction (fornix sign). We investigated whether the fornix sign could separate AD from NC, and could predict progression from aMCI to AD or NC to aMCI. We also quantified FA of the fornix to validate the fornix sign. RESULTS The fornix sign was identical to the lack of any voxels with an FA > .52 within the fornix. The fornix sign differentiated AD from NC with specificity of 1.0 and sensitivity of .56. It predicted conversion from NC to aMCI with specificity of 1.0 and sensitivity of .67, and from aMCI to AD with specificity of .94 and sensitivity of .83. CONCLUSION The fornix sign is a promising predictive imaging sign of AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available